These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 25498455)

  • 21. Evolution of ibrutinib resistance in chronic lymphocytic leukemia (CLL).
    Komarova NL; Burger JA; Wodarz D
    Proc Natl Acad Sci U S A; 2014 Sep; 111(38):13906-11. PubMed ID: 25201956
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ibrutinib as a Bruton Kinase Inhibitor in the Management of Chronic Lymphocytic Leukemia: A New Agent With Great Promise.
    Foluso O; Glick A; Stender M; Jaiyesimi I
    Clin Lymphoma Myeloma Leuk; 2016 Feb; 16(2):63-9. PubMed ID: 26775273
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLL.
    Reiff SD; Muhowski EM; Guinn D; Lehman A; Fabian CA; Cheney C; Mantel R; Smith L; Johnson AJ; Young WB; Johnson AR; Liu L; Byrd JC; Woyach JA
    Blood; 2018 Sep; 132(10):1039-1049. PubMed ID: 30018078
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ibrutinib responsive central nervous system involvement in chronic lymphocytic leukemia.
    Wanquet A; Birsen R; Lemal R; Hunault M; Leblond V; Aurran-Schleinitz T
    Blood; 2016 May; 127(19):2356-8. PubMed ID: 26994148
    [No Abstract]   [Full Text] [Related]  

  • 25. The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia.
    Brown JR; Barrientos JC; Barr PM; Flinn IW; Burger JA; Tran A; Clow F; James DF; Graef T; Friedberg JW; Rai K; O'Brien S
    Blood; 2015 May; 125(19):2915-22. PubMed ID: 25755291
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New approved indication for ibrutinib.
    Aschenbrenner DS
    Am J Nurs; 2014 Jun; 114(6):21. PubMed ID: 24869579
    [No Abstract]   [Full Text] [Related]  

  • 27. Ibrutinib: a paradigm shift in management of CLL.
    Badar T; Burger JA; Wierda WG; O'Brien S
    Expert Rev Hematol; 2014 Dec; 7(6):705-17. PubMed ID: 25387837
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevalence of
    Quinquenel A; Fornecker LM; Letestu R; Ysebaert L; Fleury C; Lazarian G; Dilhuydy MS; Nollet D; Guieze R; Feugier P; Roos-Weil D; Willems L; Michallet AS; Delmer A; Hormigos K; Levy V; Cymbalista F; Baran-Marszak F;
    Blood; 2019 Aug; 134(7):641-644. PubMed ID: 31243043
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Ibrutinib in the treatment of chronic lymphocytic leukemia and other B-cell malignancies].
    Wang M; Xu W; Li JY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Feb; 22(1):245-9. PubMed ID: 24598688
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Successful Treatment of Chronic Lymphocytic Leukemia Multifocal Central Nervous System Involvement with Ibrutinib.
    Christoforidou A; Kapsas G; Bezirgiannidou Z; Papamichos S; Kotsianidis Ι
    Turk J Haematol; 2018 May; 35(2):147-149. PubMed ID: 29391330
    [No Abstract]   [Full Text] [Related]  

  • 31. Ibrutinib for the treatment of chronic lymphocytic leukemia and mantle cell lymphoma.
    McDermott J; Jimeno A
    Drugs Today (Barc); 2014 Apr; 50(4):291-300. PubMed ID: 24918646
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia.
    Wiestner A
    Haematologica; 2015 Dec; 100(12):1495-507. PubMed ID: 26628631
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Ibrutinib prescription in B-cell lymphoid neoplasms].
    Dougé A; Ravinet A; Bay JO; Tournilhac O; Guièze R; Lemal R
    Bull Cancer; 2016 Feb; 103(2):127-37. PubMed ID: 26822906
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ibrutinib in CLL: a focus on adverse events, resistance, and novel approaches beyond ibrutinib.
    Kaur V; Swami A
    Ann Hematol; 2017 Jul; 96(7):1175-1184. PubMed ID: 28342031
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A mechanism-driven treatment for chronic lymphocytic leukemia?
    Foà R; Guarini A
    N Engl J Med; 2013 Jul; 369(1):85-7. PubMed ID: 23782159
    [No Abstract]   [Full Text] [Related]  

  • 36. Analysis of Efficacy and Tolerability of Bruton Tyrosine Kinase Inhibitor Ibrutinib in Various B-cell Malignancies in the General Community: A Single-center Experience.
    Ali N; Malik F; Jafri SIM; Naglak M; Sundermeyer M; Pickens PV
    Clin Lymphoma Myeloma Leuk; 2017 Jul; 17S():S53-S61. PubMed ID: 28760303
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The safety of Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia.
    Tran PN; O'Brien S
    Expert Opin Drug Saf; 2017 Sep; 16(9):1079-1088. PubMed ID: 28627951
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A new era of treatment for chronic lymphocytic leukaemia?
    Brown JR
    Lancet Oncol; 2014 Jan; 15(1):3-5. PubMed ID: 24332240
    [No Abstract]   [Full Text] [Related]  

  • 39. miR-155 expression is associated with chemoimmunotherapy outcome and is modulated by Bruton's tyrosine kinase inhibition with Ibrutinib.
    Guinn D; Ruppert AS; Maddocks K; Jaglowski S; Gordon A; Lin TS; Larson R; Marcucci G; Hertlein E; Woyach J; Johnson AJ; Byrd JC
    Leukemia; 2015 May; 29(5):1210-3. PubMed ID: 25486872
    [No Abstract]   [Full Text] [Related]  

  • 40. Successful use of Bruton's kinase inhibitor, ibrutinib, to control paraneoplastic pemphigus in a patient with paraneoplastic autoimmune multiorgan syndrome and chronic lymphocytic leukaemia.
    Lee A; Sandhu S; Imlay-Gillespie L; Mulligan S; Shumack S
    Australas J Dermatol; 2017 Nov; 58(4):e240-e242. PubMed ID: 28295171
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.